Showing 5341-5350 of 7316 results for "".
- New RNA Monitoring Method May Allow for Early Diagnosis of AD in Infantshttps://practicaldermatology.com/news/new-rna-monitoring-method-may-allow-for-early-diagnosis-of-ad-in-infants/2461771/A novel monitoring method that enables human skin transcriptome analysis of the mRNA in sebum) collected from the skin using a simple oil-blotting film may help diagnose atopic dermatitis earlier than is currently possible. According to a newstudy
- Sol-Gel, Searchlight Pharma Partner to Commercialize TWYNEO and EPSOLAY in Canadahttps://practicaldermatology.com/news/sol-gel-searchlight-pharma-partner-to-commercialize-twyneo-and-epsolay-in-canada/2461764/Israel’s Sol-Gel Technologies, Ltd. and Searchlight Pharma Inc. have signed exclusive license agreements for TWYNEO and EPSOLAY for the Canadian market. Both products recently launched in the U.S., and Searchlight is to commercialize in Canada over a fifteen-year term that i
- FDA Clears DeepX Diagnostics Inc.'s DermoSight for Telederm Screening of Suspicious Lesionshttps://practicaldermatology.com/news/fda-clears-deepx-diagnostics-incs-dermosight-for-telederm-screening-of-suspicious-lesions/2461763/The US Food and Drug Administration (FDA) has cleared DeepX Diagnostics Inc.’s digital dermatoscope DermoSight for teledermatology screening of suspected skin cancer lesions. DermoSight is currently cle
- Programmable 3D-printed Wound Dressing Could Improve Treatment for Burns and Aid Drug Deliveryhttps://practicaldermatology.com/news/programmable-3d-printed-wound-dressing-could-improve-treatment-for-burns-and-aid-drug-delivery/2461762/A 3D-printed wound dressing that uses advanced polymers may enhance the healing process for burn patients, aid drug delivery in cancer treatment, and help customize skin care regimens. "To treat burn victims, we can customize the shape using a 3D printer, secondly, t
- FDA Nod for Galderma's Restylane Eyelighthttps://practicaldermatology.com/news/fda-nod-for-galdermas-restylane-eyelight/2461760/The U.S. Food and Drug Administration (FDA) approved Restylane Eyelight, a hyaluronic acid (HA) dermal filler for the correction of undereye hollowing, in adults over the age of 21. Restylane Eyelight is formulated with NASHA Technology, which has a firm gel te
- Researchers Uncover Clues Driving PsO Spread and Severityhttps://practicaldermatology.com/news/researchers-uncover-clues-driving-pso-spread-and-severity/2461759/New research sheds light on the cellular changes that drive psoriasis severity and also offers important clues about how the disease spreads to other parts of the body. Specifically, the location of clusters of fibroblasts and macrophages tend to occur more commonly in the upper l
- Memory Killer Cells May Boost Survival in Melanomahttps://practicaldermatology.com/news/memory-killer-cells-may-boost-survival-in-melanoma/2461758/High levels of memory killer cells in cancer tissue may boost survival in people with melanoma, a new study shows. Certain immune T cells called tissue-resident memory cells are formed locally in the skin and other tissue and protect against infections that they have encountered before.
- Scientists Identify Genomic Cause and Potential Treatment for Disabling Pansclerotic Morpheahttps://practicaldermatology.com/news/scientists-identify-genomic-cause-and-potential-treatment-for-disabling-pansclerotic-morphea/2461756/Researchers have identified genomic variants that cause disabling pansclerotic morphea and have found a potential treatment. People with the disorder have an overactive version of a protein called STAT4, which regulates inflammation and wound healing. The work also identified a drug tha
- EULAR News: Tremyfa Data Shows Sustained Improvements in PsAhttps://practicaldermatology.com/news/eular-news-tremyfa-data-showing-sustained-improvements-in-psa/2461755/Tremfya (guselkumab) provides sustainable improvements in all minimal disease activity (MDA) domains through week 48 in adults with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumor necrosis factor inhibitors (TNFi-IR), according to new data
- News You Can Use: AARS Launches Social Media Toolkit for #Acne Awareness Monthhttps://practicaldermatology.com/news/aars-launches-social-media-toolkit-for-acne-awareness-month/2461754/The American Acne and Rosacea Society (AARS) has launched a social media toolkit to help dermatology medical professionals who are their members share #acnefacts in recognition of Acne Awareness Month in June, The toolkit is available at acneandrosacea.org/acne-awareness-social- me